Ironwood Pharmaceuticals, Inc.
IRWD
$1.27
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -22.98% | -23.18% | -20.63% | -12.48% | -6.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.98% | -23.18% | -20.63% | -12.48% | -6.25% |
| Cost of Revenue | -92.75% | -52.03% | 22.84% | -64.71% | -45.57% |
| Gross Profit | -17.39% | -21.79% | -21.24% | -1.37% | -0.49% |
| SG&A Expenses | -28.02% | -11.83% | 1.59% | 27.72% | 28.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.19% | -8.37% | 3.60% | 42.03% | 61.91% |
| Operating Income | -22.47% | -49.96% | -51.15% | -59.09% | -53.23% |
| Income Before Tax | -50.17% | 102.38% | 106.88% | 107.90% | 109.92% |
| Income Tax Expenses | -35.65% | -22.29% | -22.96% | -0.13% | 3.34% |
| Earnings from Continuing Operations | -209.77% | 97.01% | 100.09% | 99.68% | 100.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -97.70% | -92.57% |
| Net Income | -185.59% | 96.93% | 100.09% | 99.74% | 101.00% |
| EBIT | -22.47% | -49.96% | -51.15% | -59.09% | -53.23% |
| EBITDA | -21.84% | -48.97% | -50.32% | -58.29% | -52.66% |
| EPS Basic | -183.03% | 97.04% | 100.08% | 99.74% | 101.01% |
| Normalized Basic EPS | -36.38% | -75.64% | -72.49% | -76.57% | -70.58% |
| EPS Diluted | -252.13% | 96.93% | 99.91% | 99.55% | 100.66% |
| Normalized Diluted EPS | -34.80% | -74.67% | -70.22% | -73.76% | -69.31% |
| Average Basic Shares Outstanding | 2.11% | 2.27% | 2.28% | 2.16% | 2.01% |
| Average Diluted Shares Outstanding | -0.32% | -2.49% | -7.09% | -11.37% | -7.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |